CA1209504A

CA1209504A - Pyridine soluble extract of a microorganism

Info

Publication number: CA1209504A
Application number: CA000430780A
Authority: CA
Inventors: John L. Cantrell
Original assignee: Ribi Immunochem Research Inc
Current assignee: Ribi Immunochem Research Inc
Priority date: 1982-06-30
Filing date: 1983-06-20
Publication date: 1986-08-12
Also published as: IT8321852A0; DE3323094C2; FR2534271B1; DE3323094A1; JPS5917990A; IT8321852A1; GB2123006B; GB8317743D0; GB2123006A; IT1163622B; FR2534271A1

Abstract

ABSTRACT OF THE DISCLOSURE

A method of producing a purified pyridine-soluble extract of a microorganism is disclosed which contains between about 7 and 20% by weight of protein, between about 10 and 16%
by weight of sugar, and between about 35 and 55% by weight of fatty acids. The extract when combined with cell wall skeleton in a pharmaceutically acceptable medium is useful as an anti-tumor agent in the treatment of animals and humans.

Description

5(~

U-Wp-2661 - Ribi aACKGROUND OF THE INVENTION
.

The present invention is directed to a pyridine-soluble extract of a microorganism which, when combined with cell wall ~keleton (CWS), provides a pharmaceutical composition possessing antl-tumor proper~ies.
; Bacteria such as Corynebacterium parvum have been the subject of experimental work to isolate and characterize the ~omponent responsible for inducing inhibition of tumor growth [see, fos example, Anti Tumor ActivitY and Lymphoreticular Stimulation Properties of Fractions Isolated from C parvum;
Ca~trell, et al, Cancer Research 39~ pgs. 3554-3563 (September, 1979~]. Apart from anti-tumor activity, ~ has shown to be a potent stimulator of the lymphoreticular system resulting in undesirable increases in spleen and liver weigh~s and blas~o-genesis. Applicant has discovered that a pyridine-soluble extract of microorganism possesses potent anti-tumor properties without the undesirable toxic effects associated with the prior art products.
Cell wall skeleton is essentially cell wall which has had much of the protein and lipids normally found in the cell wall removed. It is a polymeric mycolic acid arabinogalactan mucopeptide containing remnants of trehalose mycolate~ ("P3") and undigested tuberculoproteinsO Cell wall skeleton is obtained from any microorganism including, but not limited to, M.smeqmatis, ~phlei, Nocardia rubra, Nocardia asteroides, Corynebacterium diphtheria, Corynebacterium ~arvum, M.kansasii, M.tuberculosis ~Strain H 37 RV and Ayoma B), and bovis Strain 951~

BCG. Additionally, cell wall skeleton may be obtained from such other microorganisms as E.coli, B.abortus and Coxiella burnettii.
Cell wall skeleton may be produced by first growing and harvesting bacteria such as M.bovis Strain BCG (Bacillus Calmette - ~uerin). The resulting whole cell residue is processed through a cell fractionator lRibi Cell Fractionator (Sorvall, Model RF~ which disrupts the cells, separating the outer envelope or cell wall from the pcotoplasmic impurities. The resulting cell walls are then subjected to a series of solvent extractions and enzymatic treatments (e.g., trypsin and/or chymotrypsin) to give purified cell wall skeleton.

It is, therefore, an object of the present invention ko provide a pharmaceutical composition containing a pyridine-soluble extract of a microorganism in combina~ion with cell wall skeletonO
It i~ another object of the invention to provide a method of producing the pyridine-soluble extract of a microorganism.
It i~ still another object oE the invention to provide a method of treating tumors in warm blooded animals and humans using the composition containing the pyridine-soluble extract of a microorganism and cell wall skeleton.

SUMMARY OF THE INVENTION

The present invention relates to pharmaceutical composi-tions comprising a pyridine-soluble extract of a miccoorganism, containing between about 7 and 20~ by weight of protein and about 10 to 16~ by weight of sugar, and about 35 to 55% by weight of fatty acids in combination with cell wall skeleton (CWS). The extract preferably contains about 12% by weight of each of protein and sugar and about 45% by weight of fatty acids.

-2-lZ~'9S~
Any microorganism may be used to obtain the pyridine-soluble extract including/ for example, M. bovis BCG, M.
~hlei, M. smegmatisf M. kansasii, Nocardia rubra, Corynebacterium diphtheriae and Corynebacterium parvum. Corynebacterium ~arvum i5 especially preferred~
Whole cells of the microorganism, preferably in the form of a paste, ar~ mixed with pyridine. The resulting mixture is separated to obtain a supernatant fraction which contains the pyridine-soluble extract and a pyridine residue. Optionally, the pyridine residue may be subjected to repeated separation proce-dure~ as described above using pyridine to remove further quant~ties of the desired extract.
The pyridine is then removed from the extract and the dried extract is dialyzed agains~ a suitable liquid such as dis-tilled water. The absence of whole cells or cell fragment contaminants is conirmed by electron microscopy. ~he resulting purified extract may then be lyophilized by known methods to obtain a stable product.
The pyridine soluble extract produced in accordance with this invention may be combined with CWS to produce a composition having potent anti-tumor activity without stimulating the induction of spleen and liver enlargements. The cancers which may be ~reated by this composition include animal tumors such as bovine squamous cell carcinoma, bovine fibrosarcoma, equine sarcoid, eguine melanoma~ equine squamous cell carcinoma, canine mammary tumors, canine adenoma and canine melanoma and human tumors such as breast tumors, lung tumors, colon tumors, malignant melanoma! squamous cell carcinomas and ovarian tumors.
The composition is preferably administered by injection in a pharmaceutically acceptable medium such as an oil-droplet emulsion directly into the tumor under conditions more particularly described below. The a~oresaid composition may be stabilized as for example, by a lyophilization procedure and then reconstituted without loss of potency.
The amount of the pyridine-soluble extract in a single injection ~or the treatment of animals is between about 375 and 2500 micrograms/milliliter. The amount of CWS is between about 125 and 375 micrograms/milliliter.

The number of milliliters of the biologic injected into the tumor is determined by the size of the tumor in accordance with the following table:

Animal Dosage According to Tumor Size Diameter of Tumor (cm) Amount of Biologic Injected (ml) 0-1 up to 0.5 1-2 0.5 ~o 2.5 2-3 2.5 to 5

3-5 5 to 10 5-8 10 to 15 greater than 8 15 to 20 The maximum dose per injection is about 40 milligrams for each of the pyridine-soluble extract and CWS. The course of treatment comprises up to six injections administered at about two week intervals.
The present composition in a suitable injection medium such as an oil-droplet emulsion is administered directly into human tumors. The amount of the pyridine~soluble extract in a single injection is be~ween about 200 and 5000 micr~ograms, pre-ferably between about 800 and 1200 micrograms, whiie the amount of CWS is be~ween absut 50 and 2000 micrograms. The-preferred sin~le dosage level for CWS is beL~een about 475 and 525 micro-grams. All of the above-mentioned dosage levels are based on a typical 70 kilograms adul~ patier,t. The injections are administered about once every week for up to a total of 15 injections.
As described above the composition for treatment of warm blooded animals and humans may be used in the form of an oil droplet emulsion. The amount of oil used is in the range of between about 0.5 and 3. n percenL by volume based on the total volume of the composition. It is preferred to use between about 0.75 and 1.5 percent by volume of the oil. Examples of such oils include ligh~ mineral oil, squalane, 7-n-hexyloctadecane, Conoco superoil and Drakeol 6 VR mineral oil (trademarks Eor oil, produced by the Pennreco Company, Butler, Pennsylvania)~
The homogeni~ed oil contairling mix~ure is then combined with a detergent which may optionally be dissolved in a saline solution prior to mixing. The amount of detergent is typically between about 0.02 and 0.25 percent by volume and preferably between about 0.10 and 0.20 percent by volume based on ~he total volume of the composition. Any common detergent material may be used including Tween-80, and Arlacel (trademarks for products produced by the Atlas Chemical Company).
The mixture resultir,g from the addition of detergent is then homogenized to form a suspension which has a high percentage o~ oil droplets coated with the active componerlts as determined by observation under a microscope.
The following examples are for illustrative purposes only and are not intended to limit or in any way redefine the invention as claimed in the claims appended hereto.

_5_ lZ~5~4~

EXAMPLE 1 - Preparation of Pyridine-Soluble Extract Erom Corynebacterium Parvum 59~Y1~1~95~8~e~59~ (P-ac~es, Strain 4182) was grown and harvested at 37 C. in NIH thioglycolate broth for between 48 and 72 hours to obtain a whole cell paste. The paste was then washed with 500 ml of distilled water. 90 grams ~wet weight) of the washed paste was mixed with 200 ml. of neat pyridine and centrifuged at 1700 x 9 for one hour at 4 C. A pyridine-soluble extract was removed as a supernatant fraction. The remaining residue was extracted with additional pyridine under identical conditions as described above. Following filtration, using Whatman No. 1 paper, the pyridine extracts were pooled and the solvent was removed by evaporation at 50 C. in a ~uchi Rotavapor ~Brinkmann Instruments, Westbury, New York). The dried pyridine extract was extensively dialyzed against distilled water and then lyophilized. The resulting purified pyridine extract contained about 12% by weight of protein, about 12~ by weight of sugar and about 45% by weight of fatty acids. The extract was examined under an electron microscope and found to be free of contaminat~
ing whole cells and cell wall fragments. The yield of the pyridine-soluble extract was 9% (8.1 g.).

EXAMPLE 2 - Preparation of Pyridine-Soluble Extract from M.bovis Strain BCG

M~ bovis strain ~CG was grown and harvested in Sautons medium at 37Co for between 3 4 weeks to oktain a washed whole cell paste. 50 grams (wet weight) of the washed paste was then treated in the same manner as Example 1 to produce a yield of the pyridine-soluble extract of 7% ~3~59)~ The extrac~ contained 15%
by weight of protein, 10% by weight of sugar and 52~ by weight of ~ZOgl5~g~

of fatty acids.

EXAMPLE 3 - Guinea-Pig Line-10 Tumor Tests Seven strain 2 guinea pigs having Line-10 tumor growths of about 9mm in diameter were injec~ed once with 0.4 ml of a sterile oil droplet emulsion, i.e., Drakeol 6 VR mineral oil tPennsylvania Refining Company, Butler, Pennsylvania), containing 300 micrograms of the pyridine-soluble extract prepared in accor-dance with Example 1 and 50 micrograms of cell wall skeleton, directly into the tumor tissue.
After three months, the animals were examined and in 6 of the 7 animals, total regression had occurred.
In a control experiment, six strain 2 guinea pigs having Line-10 tumor growths of about 9mm in diameter were injected once with 0.4 ml of the sterile oil droplet emulsion described above without the pyridine extract or cell wall skeleton. The injections were made directly into the tumor tissue. None of the six tumors showed any signs of regression after three months.

Claims

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A method of producing a purified pyridine-soluble extract of a microorganism selected from the group consisting of M. smeg-matis, M.phlei, Nocardia rubra, Nocardia asteroides, Corynebacter-ium diphtheriae, Corynebacterium parvum, M.Kansasii, M.
tuberculosis (strain H 37 RV and Ayoma B), M. Bovis Strain BCG, E.
coli, B. abortus and Coxielle burnetti, comprising:
(a) preparing a whole cell paste of said microorganism;
(b) washing said paste;
(c) treating said paste with pyridine to produce an extract and a residue;
(d) removing said pyridine from said extract; and (e) dialyzing said dried extract to obtain purified pyridine-soluble extract.

2. The process of claim 1 further comprising lyophilizing said purified pyridine-soluble extract.

3. The process of claim 1 further comprising reacting the residue with pyridine to obtain additional amounts of the pyridine-soluble extract.

4. A pyridine-soluble extract product obtained by the method of claim 1 from a microorganism selected from the group consisting of M. smegmatis, M.phlei, Nocardia rubra, Nocardia asteroides, Corynebacterium diphtheriae, Corynebacterium parvum, M.Kansasii, M. tuberculosis (strain H 37 RV and Ayoma B), M. Bovis Strain BCG, E. coli, B. abortus and Coxielle burnetti.